Vanguard Group Inc Kinnate Biopharma Inc. Transaction History

Vanguard Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.24 - $2.66 $75,888 - $90,118	33,879 Added 3.25%	1,076,789 $2.86 Million
Q4 2023 Feb 14, 2024	BUY	$1.07 - $2.5 $52,106 - $121,745	48,698 Added 4.9%	1,042,910 $2.47 Million
Q2 2023 Aug 14, 2023	SELL	$2.33 - $6.84 $71,004 - $208,442	-30,474 Reduced 2.97%	994,212 $3.01 Million
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $23,341 - $53,833	6,746 Added 0.66%	1,024,686 $6.4 Million
Q4 2022 Feb 10, 2023	BUY	$5.26 - $12.19 $34,679 - $80,368	6,593 Added 0.65%	1,017,940 $6.21 Million
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $150,562 - $240,655	15,270 Added 1.53%	1,011,347 $12.1 Million
Q2 2022 Aug 12, 2022	SELL	$7.43 - $13.0 $3.41 Million - $5.97 Million	-459,557 Reduced 31.57%	996,077 $12.6 Million
Q1 2022 May 13, 2022	SELL	$7.73 - $17.99 $3.61 Million - $8.4 Million	-466,789 Reduced 24.28%	1,455,634 $16.4 Million
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $1 Million - $1.55 Million	60,815 Added 3.27%	1,922,423 $34.1 Million
Q3 2021 Nov 12, 2021	BUY	$17.81 - $24.87 $12 Million - $16.7 Million	672,778 Added 56.59%	1,861,608 $42.9 Million
Q2 2021 Aug 13, 2021	BUY	$22.19 - $31.55 $26.4 Million - $37.5 Million	1,188,830 New	1,188,830 $27.7 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.